Lisa Rojkjaer - Feb 25, 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: Chief Medical Officer
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Stock symbol: VIRX
Transactions as of: Feb 25, 2022
Transactions value $: -$6,657
Form type: 4
Date filed: 3/1/2022, 08:12 PM
Previous filing: Nov 29, 2021
Next filing: Mar 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIRX	Common Stock	Options Exercise	$0	+4.13K	+10.73%	$0.00	42.6K	Feb 25, 2022	Direct	F1
transaction	VIRX	Common Stock	Sale	-$6.66K	-2.4K	-5.62%	$2.78	40.2K	Feb 28, 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Restricted Stock Units	Options Exercise	$0	+4.13K	+8.33%	$0.00	53.7K	Feb 25, 2022	Common Stock	4.13K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
F2	The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
F3	Represents the weighted average share price of an aggregate total of 2,395 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4	One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.